hereinafter , various embodiments of the tablets provided herein will be explained . ac220 or a pharmaceutically acceptable salt thereof which is disclosed herein has the chemical name : n -( 5 - tert - butyl - isoxazol - 3 - yl )- n ′-{ 4 -[ 7 -( 2 - morpholin - 4 - yl - ethoxy ) imidazo [ 2 , 1 - b ][ 1 , 3 ] benzothiazol - 2 - yl ] phenyl } urea , or a pharmaceutically acceptable salt thereof , which is disclosed in wo2007 / 109120 and wo2009 / 038757 . the drug may be one of various salts , hydrates , solvates , and crystalline forms of ac220 disclosed in these publications . the drug is a hydrochloride salt of ac220 in one embodiment , and ac220 . 2hcl in another embodiment . the amount of ac220 or a pharmaceutically acceptable salt thereof is not limited , so long as it is a therapeutically or prophylactically effective amount , for example , from about 12 mg to about 450 mg per day in one embodiment , from about 12 mg to about 145 mg in another embodiment , from about 30 mg to about 135 mg in still another embodiment , 30 mg , 40 mg , 45 mg , 50 mg , 60 mg , 70 mg , 80 mg , 90 mg , 120 mg , and 135 mg in still another embodiment , 60 mg in still another embodiment , and 90 mg in still another embodiment . the daily dose may be divided into multiple doses administered several times a day , if necessary . the above - mentioned amount is the amount of ac220 in one embodiment , and the amount of ac220 . 2hcl in another embodiment . it was confirmed that aggregate formation via π - π stacking between aromatic rings and network formation by intermolecular hydrogen bonding are involved , as intermolecular interactions , in gel formation of an aqueous solution of ac220 , as shown in example 1 described below . in this regard , wo 2010 / 132787 does not disclose the intermolecular interaction of ac220 , but discloses that hpbcd was added to ac220 as an anti - gelling agent in a ratio ( ac220 : hpbcd ) of 1 : 10 by weight , and the mixture was spray - dried to prepare a preparation that is dissolved before use , then the preparation was reconstituted by aqueous solution to obtain a liquid dosage form in which gelling was prevented ( for example , paragraphs [ 0073 ] to [ 0075 ] and [ 0088 ], and examples 6 to 8 ). it is suggested that the gelling in aqueous liquid dosage form was prevented as a result of suppression of the intermolecular interaction of ac220 on the basis of the examination of the intermolecular interaction of ac220 . that is to say , the composite of ac220 and hpbcd in a ratio of about 1 : 10 by weight is believed to effectively suppress the intermolecular interaction of ac220 . the composite of ac220 and hpbcd in the present disclosure is found in a ratio of ac220 or a pharmaceutically acceptable salt thereof and hpbcd by weight ranging from 1 : 8 to 1 : 20 in one embodiment , 1 : 10 to 1 : 15 in another embodiment , and 1 : 10 in still another embodiment . the composite of ac220 and hpbcd is granulated or powdered solid of mixture of ac220 and hpbcd , which is suitable for tableting and prepared by a conventional methods . the composite of ac220 and hpbcd is a spray - dried powder or a lyophilized powder in one embodiment , a spray - dried powder in another embodiment , and lyophilized powder in still another embodiment . in the case that the amount of hpbcd to ac220 is less than the above amount , there is a possibility that the intermolecular interaction of ac220 in the preparation is not completely suppressed , and the dispersion and the dissolution of such a tablet will be delayed or reduced , depending on the water content or ph in the digestive tract of a patient . in certain embodiments , the composite in the tablets provided herein is prepared by conventional methods . in certain embodiments , ac220 or a pharmaceutically acceptable salt thereof and hpbcd are dissolved in an inert solvent and stirred to obtain a mixture . in certain embodiments , the mixture is dried lyophilized or spray - dried to prepare the composite . in certain embodiments , the methods include disintegration and / or particle size regulation steps . in certain embodiments , 1 part by weight of ac220 . 2hcl and 8 to 20 parts by weight of hpbcd are dissolved in an inert solvent such as water and the mixture is spray - dried to obtain a powdered composite . the spray - dried powders obtained using 10 parts by weight of hpbcd with 1 part by weight of ac220 . 2hcl are disclosed in examples 6 to 8 of wo 2010 / 132787 . these powders are disclosed as compositions for a preparation that is dissolved before use , which is dissolved in aqueous solution and administered in a liquid dosage form , and in certain embodiments , is used as the composite in the present disclosure for the production of the tablet provided herein . in the present specification , a spray - dried powder of ac220 . 2hcl and hpbcd at a ratio of 1 : 10 by weight obtained by a similar method as disclosed in examples 6 to 8 of wo 2010 / 132787 is sometimes referred to as “ ac220 - hpbcd ( 1 : 10 )” hereinafter . the amount of the composite of ac220 and hpbcd in the tablets provided herein is such that the tablet disintegrates rapidly , and a rapid dissolution is achieved . in one embodiment , the amount of the composite with respect to the total weight of the tablet is , 50 % by weight or more , in another embodiment , 60 % by weight or more , in another embodiment , 70 % by weight or more , in still another embodiment , 80 % by weight or more , in still another embodiment , 85 % by weight or more , and in still another embodiment , and 88 % by weight or more . in certain embodiments , the tablets are coated tablets , and the amount of composite with respect to the total weight of uncoated tablets is 80 % by weight or more , in one embodiment , 85 % by weight or more , and in another embodiment , 90 % by weight or more . in certain embodiments , the tablets contain a foaming agent ( effervescent tablets ) comprising a pharmaceutically acceptable solid acid and a compound comprising a carbonate and / or a hydrogen carbonate in an amount of about 10 to 45 % by weight . in certain embodiments , effervescent tablets contain the composite in an amount of about 50 % by weight or more , in one embodiment , 55 % by weight or more , and in another embodiment , 60 % by weight or more . it was observed that when the composite of ac220 and hpbcd was used to prepare a tablet by conventional methods using excipients commonly used in the pharmaceutical field , release and dissolution were unexpectedly delayed . therefore , in one embodiment , in the tablet provided herein , the types of excipients and the amounts of excipients are appropriately selected in accordance with various conditions , for example , the type of excipient ( properties such as molecular weight , solubility , and viscosity ), the types and amounts of other excipients , the type and amount of composite , and its dosage form and the formulation step ( granulation method and tabletting method ). disintegrators are excipients to improve the disintegration of a preparation , more particularly , they are excipients to be added to disintegrate a tablet by absorbing water in the body after administration , swelling , and thereby facilitating release of the active ingredient . however , as described in reference example 3 in this specification , when general - purpose disintegrators which absorb water and swell were added to tablets containing the ac220 - hpbcd ( 1 : 10 ), no disintegration due to the swelling of the tablets was confirmed . in certain embodiments , the disintegration and the dissolution of the tablets were reduced because of certain disintegrators . in certain embodiments , the amount of disintegrators in the tablets provided herein is limited to a range in which the disintegration and the dissolution of the tablet are not reduced . in certain embodiments , the tablets do not contain any disintegrators that do not improve the disintegration . the amount of disintegrator in the tablets is selected such that the disintegration and dissolution of the tablet are not reduced . the amount of disintegrator in the tablet varies based on , for example , the types and properties of disintegrators , the types and amounts of other excipients , the type and amount of the composite , and their dosage forms and the formulation step ( granulation method and tabletting method ). in certain embodiments , the amount of disintegrator in the tablet is about 10 % by weight or less based on the total weight of the tablet , in one embodiment , 5 % by weight or less , and in another embodiment , and 3 % by weight or less . in one embodiment , the tablet provided herein does not contain any disintegrators . the disintegrators in the present disclosure are excipients which are expected to exhibit an effect of disintegrating tablets by absorbing water in the digestive tract and swelling . examples of the disintegrators include : low - substituted hydroxypropyl cellulose ( l - hpc ) ( product name : lh - 11 , lh - 21 , lh - 22 , lh - 31 , and the like ) crospovidone ( product name : kollidon cl , polyplasdone xl , crospovidone , and the like ) croscarmellose sodium ( product name : kicolate , ac - di - sol , primellose , and the like ) sodium starch glycolate ( product name : primojel , glycolys , explotab , and the like ) sodium alginate carmellose , carmellose calcium , and carmellose sodium glycerin fatty acid ester low - substituted sodium carboxymethyl starch partially pregelatinized starch ( product name : lycatab c , pcs , graflow , starch 1500 , and the like ). binders are classified as excipients which impart the stickiness for maintaining quality after tabletting . it was found that binders having a high molecular weight and binders having a high viscosity at the time of dissolution reduced the initial dissolution of the tablet provided herein . the amount of a binder in the tablets provided herein varies based on , for example , the type of binders ( properties such as molecular weight , solubility , and viscosity ), the type and amount of other excipients , the type and amount of the composite , and its dosage form and the formulation step ( granulation method and tabletting method ). in certain embodiments , the amount of the binder is about 10 % by weight or less of the total weight of the preparation , in one embodiment , the binder is about 5 % by weight or less , in another embodiment , the binder is about 3 % by weight or less . in one embodiment , the binder is about 3 % by weight . in one embodiment , the binder is about 1 % by weight . in one embodiment , the tablet provided herein does not contain any binder . in certain embodiments , a binder having a low molecular weight and a low viscosity , such as hpc - ssl - sfg , only weakly inhibits the release , and thus , the influence of the addition of the binder on the dissolution is small . by contrast , in certain embodiments , a binder having a high viscosity such as hpc - l strongly inhibits the release , and thus , it is preferable to add such binder in smaller amounts . hydroxypropyl cellulose ( product name : hpc - ssl , hpc - sl , hpc - l , metolose sr , klucel - ef , klucel - lf , klucel - jf , and the like ) hypromellose ( product name : tc - 5e , tc - 5r , tc - 5m , tc - 5s , metolose 65sh , methocel f , and the like ) methyl cellulose ( product name : metolose sm , methocel a , and the like ) hydroxyethyl cellulose hydroxyethyl methylcellulose hydroxypropyl starch povidone ( product name : kollidon , plasdone , and the like ) corn starch potato starch rice starch gelatin examples of lubricants include magnesium stearate , calcium stearate , sucrose fatty acid ester , polyethylene glycol , talc , sodium stearyl fumarate , and stearic acid . lubricants are hydrophobic , and the amount of lubricants in tablets is limited , depending on the degree of hydrophobicity of each lubricant . when a lubricant ( s ) is used in the tablet provided herein , in certain embodiments , about 0 to 2 . 5 % by weight of lubricant ( s ) is added with respect to the total weight of the tablet . in another embodiment , ( 1 ) about 0 . 5 to 1 . 5 % by weight of a lubricant ( s ) selected from the group consisting of magnesium stearate and calcium stearate with respect to the total weight of the tablet , or ( 2 ) about 0 . 5 to 2 . 5 % by weight of a lubricant ( s ) selected from the group consisting of sodium stearyl fumarate and talc , is added . in still another embodiment , about 1 % of by weight , with respect to the total weight of the preparation , of magnesium stearate is added . diluents are excipients which are used for diluting formulation components such as active ingredients and adjusting them to amounts appropriate to the formulation , and in some cases , for imparting stability , improved moldability , and the like . diluents are also referred to as fillers or bulking agents . examples of diluents include lactose , glucose , sucrose , maltose ( preferably candy powder ( containing 83 % or more of maltose )), trehalose , sugars such as lactose and fructose , sugar alcohols such as mannitol , xylitol , maltitol , sorbitol , and erythritol , and crystalline cellulose . in one embodiment , the diluent used in the tablets provided herein is d - mannitol such as granulated mannitol ( product name : parteck m100 , m200 , pearlitol 100sd , 2005d , and the like ) or crystalline cellulose ( product name : ceolus ph - 101 , ph - 102 , ph - 301 , ph - 302 , uf - 711 , uf - 702 , and the like ). another embodiment , the diluent is crystalline cellulose . still another embodiment , the diluents is crystalline cellulose ( product name : ceolus ph - 102 ). the tablet provided herein may contain various excipients other than the above - mentioned excipients , which are pharmaceutically acceptable and used as excipients . examples of the other excipients include , but are not limited to , glidants , ph adjustors , foaming agents , sweeteners , flavors , coloring agents , stabilizers , and solubilizing agents . the amount of these excipients in the tablets provided herein is selected such that the dissolution of ac220 from the tablet is not negatively affected . in one embodiment , the total amount of these excipients is about 40 % by weight or less of the total weight of the tablet , in one embodiment , the amount is 30 % by weight or less , in another embodiment , the amount is 20 % by weight or less . in certain embodiments , it was observed that the hydrophobic excipients inhibited the penetration of water into the tablet . in certain embodiments , the total amount of hydrophobic excipients in the total excipients is about 5 % by weight or less of the total weight of the tablet . in one embodiment , the total amount of hydrophobic excipients in the total excipients is about 2 % by weight or less , in another embodiment , about 1 . 5 % by weight or less , and in still another embodiment , about 1 % by weight or less . in certain embodiments , the tablets comprise a glidant selected from silicon dioxide , light anhydrous silicic acid , titanium oxide , stearic acid , and talc . in certain embodiments , the tablets comprise a ph adjustor selected from acidic substances , such as citric acid , tartaric acid , and malic acid . since ac220 exhibits a high solubility at low ph , the addition of acidic substances is expected to improve the solubility of ac220 in the lower digestive tract from the small intestine . in certain embodiments , the tablets comprise a sweetener selected from sodium saccharin , aspartame , stevia , and thaumatin . in certain embodiments , the tablets comprise a flavors selected from lemon , lemon lime , orange , and menthol . in certain embodiments , the tablets comprise a coloring agent selected from edible pigments such as food yellow no . 5 , food red no . 2 , and food blue no . 2 , edible lake pigments , and colcothar . in certain embodiments , the tablets comprise a stabilizer , i . e ., a substance capable of stabilizing ac220 . in certain embodiments , the tablets comprise a solubilizing agent selected from the above - mentioned acidic substances . in certain embodiments , the tablet provided herein is an effervescent tablet . in certain embodiments , the effervescent tablet provided herein is a tablet comprising a pharmaceutically acceptable foaming agent , in one embodiment , the tablet comprises an effervescent mixture comprising a solid acid and a compound comprising a carbonate and / or a hydrogen carbonate . in one embodiment , when the tablet is brought into contact with water , effervescence occurs and the tablet can be effectively dissolved . examples of the solid acid include citric acid and tartaric acid . examples of the compound comprising a carbonate and / or a hydrogen carbonate include calcium carbonate , sodium carbonate , and sodium bicarbonate . the tablets provided herein contain a combination of two or more excipients . the tablet provided herein is not limited , so long as it is a preparation which is defined as a general medicament . in certain embodiment , the tablet provided herein is prepared by compression - molding the composite of ac220 and hpbcd ( spray - dried powder in one embodiment , ac220 - hpbcd ( 1 : 10 ) in another embodiment ), together with an excipient ( s ) if necessary . any conventional method for obtaining a tablet can be used , for example , the methods described in pharmacopoeias such as the japanese pharmacopoeia , the u . s . pharmacopeia , and the european pharmacopoeia , may be used . the exemplary methods include : ( 1 ) a method of directly tabletting the composite of ac220 and hpbcd ( spray - dried powder in one embodiment , ac220 - hpbcd ( 1 : 10 ) in another embodiment ), together with an excipient ( s ) if necessary , and ( 2 ) a method of performing a wet granulation of the composite of ac220 and hpbcd ( together with an excipient ( s ) if necessary ) using a granulation liquid such as ethanol , acetone , or water to form granules , or performing a dry granulation of the composite of ac220 and hpbcd ( together with an excipient ( s ) if necessary ) to form granules , and compression - molding the resulting granules ( after mixing the other component ( s ) with the granules if necessary ). in the compression - molding ( tabletting ), the mixture is tabletted using a rotary tabletting machine to obtain tabletted products . examples of the apparatus for tabletting include : a rotary tabletting machine , a single punch tabletting machine , and an oil press . any tabletting conditions suitable for tablet molding can be used . in certain embodiments , tabletting pressure is used such that the tablets are not damaged during the manufacturing process . the tabletting pressure may be , for example , from about 2 kn to about 20 kn in one embodiment , and from about 5 kn to about 20 kn in another embodiment . any tablet hardness suitable for tablet molding can be used . the tablet hardness may be , for example , 80 n or more in one embodiment , and from 90 n to 200 n in another embodiment . when the tablet is coated , conventional methods may be used for coating the tablet . examples of the coating methods include pan coating and dip coating . coating agents may be appropriately added alone or in a combination of two or more in appropriate quantities . the coating rate is not limited , so long as a film may be formed on the tablet . the coating rate is , for example , from 1 % by weight to 5 % by weight of the tablet weight . the coated tablet may be dried after the coating , and any pharmaceutically acceptable drying method may be used . any pharmaceutically acceptable coating agent may be used . examples of coating agents include product name : opadry , opadry ii , and opadry amb . the composite of ac220 and hpbcd , spray - dried powder in one embodiment , ac220 - hpbcd ( 1 : 10 ) in another embodiment , exhibits excellent flow properties , and the tablet provided herein may be prepared by , optionally adding other excipients to the composite if necessary , and directly tabletting the composite or the resulting mixture . one embodiment of the tablet provided herein is a tablet prepared by directly tabletting the composite of ac220 and hpbcd or a mixture containing the composite of ac220 and hpbcd . another embodiment of the tablet provided herein is a tablet prepared by directly tabletting the spray - dried powder or a mixture containing the spray - dried powder . in still another embodiment , the tablet provided herein is a tablet prepared by directly tabletting ac220 - hpbcd ( 1 : 10 ) or a mixture containing the ac220 - hpbcd ( 1 : 10 ). still another embodiment is a film coated tablet of any of the above tablets prepared by direct tabletting . the tablet provided herein exhibits rapid dispersion and dissolution . in one embodiment , the tablet provided herein has a dissolution rate ( d30 min ) of about 85 % or more after 30 minutes from the beginning of a dissolution test of the united states pharmacopeia usp 34 - nf 29 ( paddle method , 50 rpm , 0 . 1 n hydrochloric acid , 900 ml ). in one embodiment , the dissolution rate ( d30 min ) is about 90 % or more . in one embodiment , the dissolution rate ( d30 min ) is about 95 % or more . in certain embodiments , the dissolution rate ( d15 min ) after 15 minutes from the beginning of the dissolution test is 60 % or more , 70 % or more , or 80 % or more . the tablet provided herein exhibits bioavailability equivalent to that of the preparation that is dissolved before use comprising the spray - dried material of ac220 . 2hcl and hpbcd at a 1 : 10 ratio by weight ( administered in a liquid dosage form : ac220 solution ( 1 : 10 )) disclosed in wo 2010 / 132787 . for example , the auc 0 - 24h value of the tablet in the dog ba test described below is 0 . 8 to 1 . 2 times that of ac220 solution ( 1 : 10 ) in one embodiment , 0 . 9 to 1 . 1 times in another embodiment , and 0 . 95 to 1 . 05 times in still another embodiment . the tablet provided herein has a good stability during storage . in one embodiment , dissolution of the tablet is not reduced for at least 4 months , at least 6 months , at least 8 months , at least 10 months , or at least 12 months , in conventional packaging such as a bottle with a desiccant and an aluminum pouch . examples of the tablet provided herein having such a stability during storage include a tablet or a film coated tablet in which the composite of ac220 or its pharmaceutically acceptable salt and hpbcd ( in a ratio ranging from 1 : 8 to 1 : 20 by weight ) in an amount of about 85 % by weight or more of the total weight of the preparation and : ( 1 ) a lubricant selected from the group consisting of calcium stearate and magnesium stearate in an amount of about 0 . 5 to 1 . 5 % by weight of the total weight of the preparation , or a lubricant selected from the group consisting of talc and sodium stearyl fumarate in an amount of about 0 . 5 to 2 . 5 % by weight of the total weight of the preparation , ( 2 ) a diluent selected from the group consisting of microcrystalline cellulose and d - mannitol in an amount of about 3 to 10 % by weight of the total weight of the preparation , and ( 3 ) hydroxypropyl cellulose in an amount of about 0 to 4 % by weight of the total weight of the preparation . another embodiment is a tablet or its film coated tablet in which the composite of ac220 or its pharmaceutically acceptable salt and hpbcd ( in a ratio of 1 : 10 by weight ) in an amount of about 85 % by weight or more of the total weight of the preparation and : ( 1 ) magnesium stearate in an amount of about 0 . 5 to 1 . 5 % by weight of the total weight of the preparation , and ( 2 ) microcrystalline cellulose in an amount of about 3 to 10 % by weight of the total weight of the preparation . the embodiments described below are intended to be merely exemplary , and those skilled in the art will recognize , or will be able to ascertain using no more than routine experimentation , numerous equivalents of specific compounds , materials , and procedures . all such equivalents are considered to be within the scope of the claimed subject matter and are encompassed by the appended claims . the following evaluation methods and preparation methods were used to prepare and test the tablets . in the dissolution test of the united states pharmacopeia usp 34 - nf 29 ( paddle method , 50 rpm , 0 . 1 n hydrochloric acid , 900 ml ), a dissolution rate ( d15 min ) 15 minutes after the beginning of the test and / or a dissolution rate ( d30 min ) 30 minutes after the beginning of the test were measured . a liquid - replacement dissolution test , in which a paddle method ( 50 rpm ) was started using 300 ml of 0 . 03 n hydrochloric acid ( ph 1 . 2 ), and the liquid conditions for the dissolution test were changed to ph 6 . 8 and 900 ml 30 minutes after the beginning of the test , was performed with reference to the dissolution test of the united states pharmacopeia usp 34 - nf 29 , and dissolution rates were compared with that of the preparation that is dissolved before use comprising the spray - dried material of ac220 . 2hcl and hpbcd at a 1 : 10 ratio by weight ( administered in a liquid dosage form : ac220 solution ( 1 : 10 )) disclosed in wo 2010 / 132787 . in the results of dissolution test 2 , shown in tables of the reference examples and the examples as described below , the entry showing dissolution rate almost equivalent to or close to that of ac220 solution ( 1 : 10 ) is represented as “∘”, and t showing dissolution rate obviously lower than that of ac220 solution ( 1 : 10 ) is represented as “×”. the dissolution test of the preparation that is dissolved before use disclosed in wo 2010 / 132787 was performed using 9 ml ( including 45 mg of ac220 . 2hcl ) of a reconstituted liquid dosage form ( ac220 solution ( 1 : 10 )) prepared by reconstituting spray - dried powder of ac220 . 2hcl and hpbcd ( in a ratio of 1 : 10 by weight ) which was prepared by a similar method described in examples 6 to 8 of wo 2010 / 132787 , with water so as to give a concentration of 5 mg / ml . the bioavailability of each preparation was evaluated using dogs . preparations to be tested were administered to dogs which had been fasted overnight . in the case of the known ac220 preparation that is dissolved before use comprising the spray - dried material of ac220 . 2hcl and hpbcd at a 1 : 10 ratio by weight disclosed in wo 2010 / 132787 , a reconstituted liquid dosage form ( ac220 solution ( 1 : 10 ): 27 ml ) containing 135 mg of the active ingredient was administered along with water ( 23 ml ), and in the case of tablets , tablets ( 45 mg tablet × 3 tablets ) were administered along with water ( 50 ml ). after the preparations were orally administered , blood was collected periodically over time . the drug concentration in plasma ( ng / ml ) was measured , and the maximum concentration in blood ( cmax : ng / ml ) and the auc from 0 to 24 hours ( auc 0 - 24h : ng * h / ml ) were calculated . this test was performed using dogs the stomach conditions of which were acidic , assuming that the preparation will be administered to healthy people . a mixture of drug powder and excipients was compressed into tablets using an oil press . the drug powder and excipients were mixed in a mortar or a bag . in tables of the reference examples and the examples below , direct compression is represented as “ dc ”. a mixture of drug powder and desired excipients other than lubricants was compressed using an oil press , and pulverized using a mortar and a pestle or the like to obtain a granulated product . the resulting granulated product was mixed with a lubricant , and this mixture was compressed into tablets using an oil press with a tabletting pressure of 2 kn or 5 kn . in tables of the reference examples and the examples below , a method of obtaining tablets by the dry granulation and the compression using an oil press with a tabletting pressure of 2 kn or 5 kn is represented as “ granul . ( 2 kn )” or “ granul . ( 5 kn )”, respectively . commonly used excipients were used to obtain the tablets containing 45 mg of ac220 . 2hcl ( 45 mg tablets ) with the formulations shown in table 1 . these tablets were evaluated by dissolution test 1 . further , tablets of refs . 1c , 1d , and 1e were evaluated by dissolution test 2 . the results are shown in table 1 . refs . 1a and 1b were standard formulations , but formed a gel - like aggregate , and showed very poor disintegration and low dissolution rate . ref . 1c in which a large amount of disintegrators was added also showed poor disintegration , and sufficient dissolution could not be obtained . since ac220 has high solubility at low ph , a formulation with a ph adjustor was performed as ref . 1d . the tablet of ref . 1d showed good initial dissolution in dissolution test 1 . in the tablet of ref . 1e to which a forming agent was added , the disintegration was improved , but the initial dissolution was 72 %, which was not sufficient . in dissolution test 2 , all the tablets of refs . 1c , 1d , and 1e showed dissolution rates lower than that of the preparation that is dissolved before use disclosed in wo 2010 / 132787 at all the measuring points ( times ). a solid dispersion ( 1 : 3 ) of ac220 with polyvinylpyrrolidone ( pvp ) was prepared by spray - drying , and was used to prepare the tablets ( 45 mg tablets ) with the formulations shown in table 2 . the results of dissolution test 1 are shown in table 2 . in dissolution test 1 , the dissolution rate was improved by the addition of a ph adjustor ( ref . 2b ). however , the disintegration and the dissolution tended to decrease by the addition of disintegrators ( refs . 2c and 2d ). the tablet of ref . 2e , which showed a good result in dissolution test 1 , was used to perform the dog ba test . the results are shown in fig2 . the auc from 0 to 24 hours of ref . 2e was significantly poorer than that of the preparation that is dissolved before use comprising the spray - dried material of ac220 . 2hcl and hpbcd at a 1 : 10 ratio by weight ( administered in a liquid dosage form : ac220 solution ( 1 : 10 )) disclosed in wo 2010 / 132787 . the results suggested that the bioavailability of the tablet could not be improved even if the solubility of ac220 was improved using its solid dispersion . ac220 - hpbcd ( 1 : 10 ) which is a spray - dried powder of ac220 . 2hcl and hpbcd at a 1 : 10 ratio by weight obtained by a similar method as disclosed in examples 6 to 8 of wo 2010 / 132787 , was used to prepare the tablets ( 45 mg tablets ) of the conventional formulations as shown in table 3 . as shown in refs . 3c and 3e , the results of dissolution test 1 showed a trend toward improvement when the amounts of disintegrators were increased , but the disintegration of each tablet was not sufficient in any of the formulations , and a tablet exhibiting an initial release ( d30 min & gt ; 85 %) could not be obtained . to confirm the influence of hpbcd on preparations , hpbcd which did not contain ac220 was used to prepare the tablets ( 45 mg tablets ) with the formulations shown in table 4 , and disintegration was observed . the results are shown in table 4 . it was confirmed that disintegration was decreased in accordance with an increase in the amount of hpbcd . the molecular state of ac220 in the aqueous solution was examined . ac220 was soluble in water but a gelation of the aqueous solution of ac220 was observed with an increase in the concentration of ac220 . 1 h chemical shift displacements in this gelation were measured . the results are shown in fig1 . the protons of d and e could not be analyzed due to the overlapping with other proton signals . the 1 h signals of around the central aromatic rings shifted upfield , which suggested that the aromatic rings were strongly involved in the gel formation . further , the interaction of protons between the ac220 molecules was studied by noesy ( nuclear overhauser effect correlated spectroscopy ), which is a two - dimensional nmr method to detect protons which are spatially adjacent to each other , and as a result , cross peaks were observed at the central aromatic rings , and it was confirmed that π - π stacking between the aromatic rings was involved in the gel formation . furthermore , the hill coefficient was calculated from the analysis of the 1 h chemical shift displacements : the value was greater than 1 , and indicated a network formation . it was confirmed that the addition of methanol to the ac220 aqueous solution inhibited the gel formation , and that the network was formed by intermolecular hydrogen bonding . as described above , it was confirmed that ac220 had intracellular interactions consisting of an aggregate formation via π - π stacking and a network formation by hydrogen bonding and which were involved in the gel formation of the aqueous solution of ac220 . on the other hand , wo 2010 / 132787 discloses that hpbcd was added to ac220 as an anti - gelling agent in a ratio ( ac220 : hpbcd ) of 1 : 10 by weight , and the mixture was spray - dried to prepare a preparation that is dissolved before use , then the preparation was reconstituted by aqueous solution to obtain a liquid dosage form in which gelling was prevented ( for example , paragraphs [ 0073 ] to [ 0075 ] and [ 0088 ], and examples 6 to 8 ). the above finding suggested that the gelling in aqueous liquid dosage form was prevented as a result of suppression of the intermolecular interaction of ac220 . that is to say , it is suggested that tablets which have suppressed intermolecular interaction of ac220 can be provided by using the composite of ac220 and hpbcd in a ratio of about 1 : 10 by weight . as shown in table 5 , ac220 - hpbcd ( 1 : 10 ) and magnesium stearate as a lubricant were dry - granulated and compressed to tablets ( 45 mg tablets ). the moldability of each tablet was good , for example , the average tablet hardness ( over 10 tablets ) was 159 n . the results of dissolution tests 1 and 2 are shown in table 5 . it was confirmed that the tablet exhibited a dissolution rate equivalent to that of the preparation that is dissolved before use ( administered in a liquid dosage form : ac220 solution ( 1 : 10 )) disclosed in wo 2010 / 132787 in dissolution test 2 . as shown in table 5 , ac220 - hpbcd ( 1 : 10 ) and lubricants were compressed into tablets ( 45 mg tablets ). the moldability of each tablet was good . the results of dissolution tests 1 are shown in table 5 . when magnesium stearate with a high hydrophobicity was used as a lubricant , it was confirmed that the initial dissolution was suppressed when 2 % of magnesium stearate was added ( ex . 3c ). in contrast , the initial dissolution was good in the tablet ( ex . 3d ) to which 2 % of sodium stearyl fumarate with a slightly poor hydrophobicity was added , and thus , it was suggested that the dissolution from tablets comprising the composite could be controlled by controlling the amount of lubricants dependent on their hydrophobicity . ac220 - hpbcd ( 1 : 10 ) was used to prepare the effervescent tablets ( 45 mg tablets ) with the formulation shown in table 6 . the moldability was good . the result of dissolution test 1 is shown in table 6 . the effervescent tablets were rapidly disintegrated , and the initial dissolution was good . further , it was confirmed that the effervescent tablets exhibited a dissolution rate equivalent to that of the preparation that is dissolved before use ( administered in a liquid dosage form : ac220 solution ( 1 : 10 )) disclosed in wo 2010 / 132787 in dissolution test 2 . ac220 - hpbcd ( 1 : 10 ) was used to prepare the tablets ( 45 mg tablets ) with the formulations shown in table 7 . the moldability was good . the result of dissolution test 1 is shown in table 7 . all the tablets were rapidly disintegrated , and the initial dissolution was good . further , the tablets of ex . 5a were used to perform the dog ba test ( n = 6 ). the results are shown in fig2 , along with the results of the preparation that is dissolved before use ( administered in a liquid dosage form : ac220 solution ( 1 : 10 )) disclosed in wo 2010 / 132787 . the auc from 0 to 24 hours of ex . 5a was 0 . 96 times that of the ac220 solution ( 1 : 10 ), i . e ., equivalent thereto . further , it was confirmed that the dissolution of the tablets was not changed after the tablets had been stored in bottles with a desiccant or aluminum pouches under accelerated conditions ( 40 ° c ./ 75rh %) for 6 months , and the tablets were extremely stable preparations in which the dissolution did not decrease after long - term storage . the tablets of ex . 5a obtained in example 5 were coated with a film coating agent ( product name : opadry ii 85f18422 , colorcon , usa ; 15 mg / tablet ) to obtain coated tablets having a tablet size of 15 mm × 8 mm and a weight of 555 . 0 mg . the type and the amount of binders were varied as shown in tables 8 and 9 , and the tablets with the formulations shown in tables 8 and 9 were prepared in a similar fashion to example 5 . the results of dissolution test 1 are shown in table 8 , along with the results of ex . 5a described in example 5 . the initial dissolution tended to decrease when the amount of binders increased . it was confirmed that the criteria of high initial dissolution could be achieved by adding about 5 % of a binder , sometimes depending on the type of binders . the type and the amount of disintegrators were varied as shown in tables 10 and 11 , and the tablets with the formulations shown in tables 10 and 11 were prepared in a similar fashion to example 5 . the results of dissolution test 1 are shown in table 10 , along with the results of ex . 5a described in example 5 . the initial dissolution tended to decrease when the amount of a certain disintegrator increased . sometimes depending the type of other excipients and disintegrators , it was confirmed that the initial dissolution did not remarkably decrease when about 10 % of a disintegrator was added . however , when 10 % of a disintegrator was added , the disintegration of tablets were not observed , and the dissolution profile showed a erosion pattern . these results suggested that it was difficult to improve the disintegration by the use of disintegrators in tablets of the ac220 - hpbcd composite . the examples set forth above are provided to give those of ordinary skill in the art with a complete disclosure and description of how to make and use the claimed embodiments , and are not intended to limit the scope of what is disclosed herein . modifications that are obvious to persons of skill in the art are intended to be within the scope of the following claims . all publications , patents , and patent applications cited in this specification are incorporated herein by reference as if each such publication , patent or patent application were specifically and individually indicated to be incorporated herein by reference .
provided herein is a tablet comprising , as a drug , n -- n ′- imidazobenzothiazol - 2 - yl ] phenyl } urea or a pharmaceutically acceptable salt thereof , which is a medicament for treating acute myeloid leukemia , the tablet characterized by comprising a composite of n -- n ′- imidazobenzothiazol - 2 - yl ] phenyl } urea or a pharmaceutically acceptable salt thereof and hydroxypropyl - β - cyclodextrin in a ratio ranging from 1 : 8 to 1 : 20 .